-
Uncategorized1 week ago
Legend soars on ‘best-in-class,’ ‘best-in-disease’ in vivo CAR T in early lymphoma study
All six non-Hodgkin lymphoma patients on Legend Biotech’s CAR T therapy responded to treatment—findings that could make the biotech an attractive takeover target, according to analysts...
-
Uncategorized1 week ago
Lilly targets kidney disease with Ascidian’s RNA exon editors for up to $1.9B
For an investment of up to $1.9 billion, Eli Lilly will be able to use Ascidian Therapeutics’ platform that removes mutated exons from mRNA molecules, avoiding...
-
Uncategorized1 week agoLilly, Ascidian Launch Up-to-$1.9B RNA Exon Editor Collaboration Targeting Inherited Kidney Diseases
Eli Lilly has expanded its genetic medicines pipeline and capabilities, agreeing to partner with Ascidian Therapeutics to develop RNA exon editors intended to treat inherited kidney...
-
Uncategorized1 week agoLilly, Ascidian link up in RNA exon editing pact
Worth as much as $1.9 billion, the deal directs Ascidian to help Lilly find potential drugs for genetically driven kidney diseases. Read More
-
Uncategorized1 week ago
Spatial Single‑Cell Platform Reveals Barriers to Antibody Delivery in Solid Tumors
Targeting solid tumors remains one of oncology’s most persistent challenges. Even when a therapeutic antibody is well‑designed, and its molecular target is clear, the drug often...
-
Uncategorized1 week agoTop ultra-processed food researchers call for sweeping policy change: ‘The system is rigged’
The all-star lineup of ultra-processed food researchers who teamed up on a new special edition of the American Journal of Public Health have an overarching message...
-
Uncategorized1 week ago
Facing pressure from China, BioSpace’s NextGen biotech leaders say: ‘Bring it on’
From Chinese innovation to AI, biotech CEOs are being hit with challenges at a breakneck pace. Three leaders from BioSpace’s NextGen Class of 2026 told us...
-
Uncategorized1 week ago
No longer a bargain pool, Chinese biotechs command higher premiums
Deal dynamics between Chinese biotechs and global pharma companies are changing fast, with the biotechs seeking higher upfront payments and the Big Pharmas seeking more expansive...
-
Uncategorized1 week agoSenior NIH scientist, research fellow charged with bringing deactivated mpox virus into U.S.
DETROIT — Two scientists at a U.S. government lab were charged with smuggling vials of deactivated mpox virus into the country from Africa and lying about...
-
Uncategorized1 week ago
Programmable control of bacterial operons with a single Cas13 RNA effector
Nature Biotechnology, Published online: 03 June 2026; doi:10.1038/s41587-026-03159-4 The SONAR system enables RNA-level control of bacterial operons using a single engineered Cas13 effector that can be...
Laser‑Driven Phase Contrast Enhances Cryo‑EM Resolution of Small Proteins
STAT+: Updated: Tracking RFK Jr.’s promises to remake health in America
